Stockscreener 앱 받기
0.6552
3.15%
-0.0213
시간 외 거래:
.65
-0.0052
-0.79%
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder with Successful Cohort Treatment - Quiver Quantitative
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder - Weekly Voice
No serious adverse events as Yale, Johns Hopkins test AUD drug - Stock Titan
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine secures six patents in Hong Kong By Investing.com - Investing.com South Africa
Aug Patterns: How do insiders feel about Clearmind Medicine Inc - baoquankhu1.vn
Clearmind Medicine secures six patents in Hong Kong - Investing.com
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies - The Manila Times
Clearmind Medicine Inc. Announces Publication of Six Patents in Hong Kong for Novel Psychedelic Combination Therapies - Quiver Quantitative
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
SciSparc discloses patent application for depression yherapy - TipRanks
NeuroThera, Clearmind Advance Non-Hallucinogenic Depression Therapy With New Patent Filing - TipRanks
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
Non-hallucinogenic depression combo MEAI-PEA seeks Hong Kong patent - Stock Titan
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - TheNewswire
NeuroThera LabsClearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Yahoo Finance
Clearmind advances enrollment in alcohol disorder drug trial By Investing.com - Investing.com Nigeria
Clearmind files patent for obesity, liver disease treatment combo - Investing.com Nigeria
Clearmind files Hong Kong patent for depression treatment combo - Investing.com India
Clearmind files Hong Kong patent for depression treatment combo By Investing.com - Investing.com Australia
Clearmind Medicine Inc. Announces Hong Kong Patent Filing for Depression Therapy - marketscreener.com
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy - Bitget
Clearmind Medicine Inc. Files Patent for Innovative Non-Hallucinogenic Therapy Combining MEAI and PEA to Address Major Depressive Disorder - Quiver Quantitative
Clearmind Medicine (NASDAQ: CMND) files Hong Kong patent for MEAI-PEA depression therapy - Stock Titan
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
Clearmind advances enrollment in alcohol disorder drug trial - Investing.com India
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results - Bitget
NeuroThera and Clearmind Advance Patent for Obesity and Liver Disease Therapy - TipRanks
Clearmind Medicine Inc. Advances Enrollment for Third Cohort in Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Non-hallucinogenic AUD drug CMND-100 moves into third trial cohort - Stock Titan
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - TheNewswire
NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Yahoo Finance
Clearmind files patent for obesity, liver disease treatment combo By Investing.com - Investing.com Canada
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
Clearmind gets safety board approval to continue AUD trial - Investing.com Nigeria
Clearmind gets safety board approval to continue AUD trial By Investing.com - Investing.com Canada
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval - Bitget
Clearmind (Nasdaq: CMND) moves CMND-100 alcohol-use trial into higher-dose stage - Stock Titan
Clearmind Medicine IncDSMB approves continuation of Phase I/IIa CMND-100 trial in AUD - marketscreener.com
Alcohol use disorder drug from Clearmind moves to higher-dose testing - Stock Titan
CMND Earnings History & Surprises | EPS & Revenue Results | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
1.20%
0.06%
자본화:
|
볼륨(24시간):